Abstract
Neurological diseases present significant therapeutic challenges due to the complexity of the central nervous system (CNS) and the presence of the blood-brain barrier (BBB), which limits drug delivery. Recent advances in drug delivery systems (DDS) have enabled more effective and targeted treatment strategies for CNS disorders such as Alzheimer's disease, Parkinson's disease, epilepsy, and glioblastoma. This article reviews the latest innovations in DDS, including nanoparticle-mediated delivery, intranasal systems, and bioresponsive platforms, with a focus on overcoming physiological barriers and improving clinical outcomes.
All articles published in the American Journal of Pharmacy and Pharmacology are licensed under the Creative Commons Attribution 4.0 International License (CC BY 4.0). This license allows others to:
-
Share — copy and redistribute the material in any medium or format
-
Adapt — remix, transform, and build upon the material for any purpose, even commercially
Under the following terms:
-
Attribution — Appropriate credit must be given to the original author(s) and source, a link to the license must be provided, and any changes made must be indicated.
By submitting their work, authors agree to these licensing terms and retain copyright of their articles.